Top Markets
Coin of the day
Sunshine Biopharma, Inc. Sunshine Biopharma, Inc.

Sunshine Biopharma, Inc.

SBFM
Rank in Stocks #39262
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of... Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Share Price
$1.16
Last synced: 2026-07-31
Market Cap
$580.69K
Change (1 day)
-5.69%
Change (1 year)
-92.32%
Country
US
Trade Sunshine Biopharma, Inc. (SBFM)

Category

Revenue for Sunshine Biopharma, Inc. (SBFM)
Revenue in Aug 2026 TTM: 0
According to Sunshine Biopharma, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Sunshine Biopharma, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors